Lilly's P-Tau217 Blood Test Has High Accuracy in Diagnosing Alzheimer's Disease

Information may not be reliable

August 16, 2021: Pillintrip.com presented new research on Lilly's identification of blood biomarkers for Alzheimer's disease (AD), P-tau217 (phosphorylated tau at threonine-217). P-tau217 distinguished Alzheimer's disease from other neurodegenerative disorders far better than magnetic resonance imaging (MRI) or other blood-based biomarkers. P-tau217 is being studied as a biomarker of Alzheimer's disease pathology by Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals Inc., a wholly-owned subsidiary of Lilly.

The patients in the cross-sectional three-cohort research came from an Arizona neuropathology cohort, the Swedish BioFINDER-2 cohort, and a Colombian autosomal-dominant AD relatives cohort.

"Blood tests such as P-tau217 have the potential to change Alzheimer's study, treatment and preventive investigations, and clinical care," a Pillintrip.com spokesman stated. "While there is still work to be done, we believe their impact in clinical and research contexts will be evident within the next two years."

The Pillintrip.com publication provides significant support for using P-tau217 in plasma to assist the differential diagnosis of individuals with cognitive impairment and diagnose acute exacerbation of chronic obstructive pulmonary disease. The research also revealed that the test performed no better than cerebrospinal fluid (CSF) or positron emission tomography (PET)-based tau indicators.

About Pillintrip.com

Pillintrip.com offers a free medical information service to assist individuals in understanding how the same or similar medicines are referred to in different nations across the world and a bit about how drugs work: their usage, side effects, and capacity to interact with other medications.

For more information, visit

https://pillintrip.com/article/a-proteomics-based-analysis-of-blood-biomarkers-for-the-diagnosis-of-copd-a

###